Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Wirksamkeit der Ernährung auf die Lebensqualität bei Multipler Sklerose (EDQ)

15. September 2026 aktualisiert von: Terry L. Wahls

The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.

Studienübersicht

Detaillierte Beschreibung

In the United States, MS affects nearly 1 million people with a 2.8:1 female to male ratio and the highest incidence rates among whites and African Americans. The economic cost of managing MS is substantial. In the U.S., the total medical costs for patients with MS increased from $116 million in 2002 to $198 million in 2013. MS is a chronic, neuroinflammatory, and neurodegenerative disease-causing symptoms of pain, fatigue, and changes in vision, cognition, and movement that greatly reduce quality of life (QoL) and the ability to maintain employment.

The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care. The primary objective of this study is to evaluate the effect of two dietary interventions (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination) on MS QoL compared to usual care control (Dietary Guidelines for America), and the secondary objectives and the long-term effects on, motor function, low-contrast vision sensitivity, fatigue, mood, and disease activity assessed by brain imaging.

The proposed study will consist of study participants attending 3 in-person site visits, months 0, 3, and 24, and online surveys every 3 months (months 0-24).

This study will use a randomized single-blind controlled design to test the short-term (6 months) and long-term (an additional 18 months) impact of the intervention diets on symptoms of MS including QoL and related outcomes stated above. We will use a fourteen-day run-in period to identify participants who are most likely to be successful in completing study procedures; this process has been effective in our previous studies. Participants who successfully complete all baseline self-reported outcomes and follow all study procedures during the seven-day run-in period will be scheduled for an on-site baseline visit for randomization to one of three diets (time restricted olive oil based (TROO) ketogenic and modified Paleolithic elimination and Dietary Guidelines for America).

On-site study visits will include blood draws, motor, cognitive, vision function assessments, and MRI. Motor assessments will include a 6-minute walk test, 25-foot walk test, 9-hole pegboard to test hand function, symbol digit exercise to test thinking functions, and critical flicker fusion test, ocular coherence tomography and low contrast vision sensitivity to test vision. The study participant will be escorted to the MRI unit to complete a non-contrast MRI of the brain. At the baseline visit, participants will be randomized. Participants assigned to the intervention diets will be given intervention specific educational materials including shopping lists, example menus and recipes, and the study supplements. Study participants randomized to the dietary guidelines for Americans diet will receive emails and/or text messages (approximately 3-6 weeks) to receive resources with websites for the Dietary Guidelines of America, and recent multiple sclerosis-related research that does not involve diet.

Study team will provide fish oil, essential fatty acids, and phosphatidylcholine to the two intervention groups only. The participant will be scheduled for a Zoom video conference meeting with the assigned registered dietitian to review the assigned study diet.

In addition, subjects will collect saliva specimens for microbiome analysis at each of the 3 site study visits (months 0, 3 and 24).

Dietary History Questionnaire III will be completed at months 0, 3, 12 and 24 and will be used to assess adherence to the assigned dietary pattern.

The online questionnaires sent to participants every 3 months will also be used to track supplement intake, medication use, and details about health & life events, MS symptoms, fatigue, quality of life, doctor's appointment, and side effects they may be experiencing.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

162

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Eligibility for the run-in phase of the study:

Participants will be eligible to enroll in the fourteen-day run-in phase of the study if they meet the following inclusion and exclusion criteria:

INCLUSION CRITERIA:

  • A definitive diagnosis of RRMS based on the 2017 revised McDonald Criteria.
  • The ability to prepare, or availability of someone to prepare, home-cooked meals.
  • Must own a computer, smartphone, or tablet device that has internet access to complete online surveys and capable of running study related applications.
  • Must be willing to follow study procedures outlined and explained to them.
  • Be between the ages of 18 to 70 at the time of consent.
  • Must be able to walk 25 feet without support.
  • Willingness to be randomized and follow any of the study diets.
  • Must consent to sharing the clinical notes from their primary care and neurology providers during the study period.

EXCLUSION CRITERIA:

  • Moderate or severe mental impairment.
  • Use of insulin, Coumadin, weight loss medications such as orlistat that causes fat malabsorption.
  • Worsening of symptoms resulting in the initiation or change of treatment including steroids (solumedrol, prednisone, etc.) or disease-modifying medications in 4 weeks prior to consent.
  • Treatment for cancer by radiation or chemotherapy in 12 months prior to consent, other than skin cancer.
  • Diagnosis of clinically significant heart disease, liver disease, kidney disease, or history of oxalate kidney stones.
  • Diagnosis of type II diabetes that does not have approval from treating physicians to adopt any of the 3 study diets.
  • Clinical diagnosis of moderate to severe psychiatric disease that makes study adherence more difficult (e.g., schizophrenia, bi-polar disease, severe depression and/or anxiety).
  • An active eating disorder such as anorexia, bulimia, binge eating, or orthorexia.
  • Measurement of BMI <20.
  • Confirmation of pregnancy or planning to become pregnant in the next 2 years.
  • History of diagnosed fat intolerance/malabsorption such as cholecystectomy or uncontrolled exocrine pancreatic insufficiency.
  • Participation in another research study investigating MS treatments, diet, or exercise.
  • Presence of a contraindication to completing a brain MRI or having claustrophobia which interferes with completion of MRI studies without the use of sedation.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Group 1 (Modified paleolithic elimination diet).

Modified paleolithic elimination diet.

nutraceutical supplement

Andere Namen:
  • 1400 mg Linolsäure/350 mg Linolensäure

nutraceutical supplement

Andere Namen:
  • 315 mg Eicosapentaensäure/ 105 mg Docosahexaensäure

nutraceutical supplement

Andere Namen:
  • 1300 mg Phosphatidylcholin
  1. Complete elimination of all gluten-, dairy-, and egg-containing foods.
  2. Increase fruit and vegetable intake to 6-9 servings/day comprising of 2-3 servings each of the following categories: intensely colored, sulfur-rich, and leafy greens.
  3. Consume 6-12 ounces/day protein including organ meats and fatty fish.
  4. Consume fermented foods daily.
  5. Consume daily servings of algae, seaweed, and nutritional yeast.
Experimental: Group 2 (TROO)

Time Restricted Olive Oil Based (TROO) Ketogenic Diet

nutraceutical supplement

Andere Namen:
  • 1400 mg Linolsäure/350 mg Linolensäure

nutraceutical supplement

Andere Namen:
  • 315 mg Eicosapentaensäure/ 105 mg Docosahexaensäure

nutraceutical supplement

Andere Namen:
  • 1300 mg Phosphatidylcholin
  1. Restriction of dietary carbohydrates to < 50 grams/day.
  2. Use olive oil (cold-pressed extra virgin preferred) to increase fat intake to >160 grams/day.
  3. Consume <100 grams/day protein.
  4. Limit dairy to 2 servings/day of whole fat options (completely exclude reduced fat dairy).
  5. Consume at least 3 servings/day non-starchy vegetables.
Aktiver Komparator: Group 3 Control

Usual diet with Dietary Guidelines for Americans Diet information

  1. Limit sodium to < 2,300 mg/day.
  2. Limit added sugar and saturated fat intake to <10% of kcal/day, respectively.
  3. Consume 5 servings of fruits and vegetables per day.
  4. Consume 6-9 ounce equivalents/day of grains, making at least half whole grain options.
  5. Consume 3 servings of reduced fat dairy per day.
  6. Consume 6 ounces/day protein foods.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Zeitfenster: baseline to 3 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 3 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Zeitfenster: baseline to 6 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 6 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Zeitfenster: baseline to 12 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 12 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Zeitfenster: baseline to 18 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 18 Months
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Zeitfenster: baseline to 24 Months

Change in (MS 54 QoL MH) survey questions mean scores, range 0-100, higher number is better.

baseline to 24 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Zeitfenster: baseline to 3 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 3 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Zeitfenster: baseline to 6 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 6 Months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Modified Fatigue Impact Scale (MFIS)
Zeitfenster: baseline to 3 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 3 months
Modified Fatigue Impact Scale (MFIS)
Zeitfenster: baseline to 6 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 6 months
Modified Fatigue Impact Scale (MFIS)
Zeitfenster: baseline to 12 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 12 months
Modified Fatigue Impact Scale (MFIS)
Zeitfenster: baseline to 18 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 18 months
Modified Fatigue Impact Scale (MFIS)
Zeitfenster: baseline to 24 months

Change in MFIS survey questions, scores range from 0-84, lower score is better.

baseline to 24 months
Hospital Anxiety Depression Scale (HADS)
Zeitfenster: baseline to 3 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 3 months
Hospital Anxiety Depression Scale (HADS)
Zeitfenster: baseline to 6 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 6 months
Hospital Anxiety Depression Scale (HADS)
Zeitfenster: baseline to 12 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 12 months
Hospital Anxiety Depression Scale (HADS)
Zeitfenster: baseline to 18 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 18 months
Hospital Anxiety Depression Scale (HADS)
Zeitfenster: baseline to 24 months

Change in HADS survey question score, a 14 question scale ranging from 0-3 with zero being being low or no occurrence and 3 being high occurrence

baseline to 24 months
Fatigue Severity Scale score (FSS)
Zeitfenster: Baseline to 3 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 3 months
Fatigue Severity Scale score (FSS)
Zeitfenster: Baseline to 6 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 6 months
Fatigue Severity Scale score (FSS)
Zeitfenster: Baseline to 12 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 12 months
Fatigue Severity Scale score (FSS)
Zeitfenster: Baseline to 18 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 18 months
Fatigue Severity Scale score (FSS)
Zeitfenster: Baseline to 24 months

Change in FSS survey question mean scores, scores range from 1-7, lower is better.

Baseline to 24 months
Brain volume as measured by non contrast magnetic resonance imaging (MRI)
Zeitfenster: baseline to 24 months

Change in MRI grey matter brain volume, more is better

baseline to 24 months
Brain lesions as measured by non contrast magnetic resonance imaging (MRI)
Zeitfenster: baseline to 24 months

Change in inflammatory lesions numbers as measured by non contrast brain MRI, fewer is better

baseline to 24 months
Timed 25 foot walk test
Zeitfenster: baseline to 3 months

seconds required to walk 25 feet, lower is better

baseline to 3 months
Timed 25 foot walk test
Zeitfenster: baseline to 24 months

seconds required to walk 25 feet, lower is better

baseline to 24 months
9 Hole peg board test
Zeitfenster: baseline to 3 months

seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better

baseline to 3 months
9 Hole peg board test
Zeitfenster: baseline to 24 months

seconds require to move 9 pegs to various locations on a peg board, fewer seconds is better

baseline to 24 months
Low contrast visual acuity
Zeitfenster: baseline to 3 months

A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better.

baseline to 3 months
Low contrast visual acuity
Zeitfenster: baseline to 24 months

A measure of best corrected vision, measure is log minimal angle of resolution at 2.5% contrast. Lower number is better.

baseline to 24 months
Dietary History Questionnaire IIi
Zeitfenster: baseline to 12 months

Change in dietary intake measured by survey questions

baseline to 12 months
Dietary History Questionnaire IIi
Zeitfenster: baseline to 3 months

Change in dietary intake measured by survey questions

baseline to 3 months
Critical flicker fusion
Zeitfenster: baseline to 3 months

change in The herz at which a flickering light is seen as non-flickering as measured by herz

baseline to 3 months
Critical flicker fusion
Zeitfenster: baseline to 24 months

change in The herz at which a flickering light is seen as non-flickering as measured by herz

baseline to 24 months
Ocular Coherence tomography
Zeitfenster: baseline

Measure of optic nerve and retina depths using infrared light technology

baseline
Ocular Coherence tomography
Zeitfenster: baseline to 3 months

change in the Measure of optic nerve and retina depths using infrared light technology

baseline to 3 months
Ocular Coherence tomography
Zeitfenster: baseline to 24 months

change in the Measure of optic nerve and retina depths using infrared light technology

baseline to 24 months
Neurofilament light chain
Zeitfenster: baseline to 3 months

blood biomarker of neuroaxonal (brain) damage

baseline to 3 months
Neurofilament light chain
Zeitfenster: baseline to 24 months

blood biomarker of neuroaxonal (brain) damage

baseline to 24 months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Zeitfenster: baseline to 12 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 12 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Zeitfenster: baseline to 18 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 18 Months
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Zeitfenster: baseline to 24 Months

Change in (MS 54 QoL PH) survey questions mean scores, range 0-100, higher number is better.

baseline to 24 Months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Terry L Wahls, MD, University of Iowa

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

10. Februar 2022

Primärer Abschluss (Geschätzt)

1. Oktober 2026

Studienabschluss (Geschätzt)

1. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

9. August 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. August 2021

Zuerst gepostet (Tatsächlich)

16. August 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Data that has been published will be shared if requested by a scientist conducting a PROSPERO registered meta-analyses who has signed a data use agreement with the University of Iowa Department of Sponsored Programs.

IPD-Sharing-Zeitrahmen

One year after the specific data has been published.

IPD-Sharing-Zugriffskriterien

A scientist who has a PROSPERO registered meta-analysis whose meta-analysis protocol has been published. The scientist must contact the PI using their academic email, provide the published PROSPERO registered meta-analysis protocol manuscript, specify which data is being requested. Upon review of the submitted documents, the PI will initiated an outcoing material data use agreement with the Division of Sponsored Programs at the University of Iowa outlining the terms of use. After signing the approved contract, the data will be released to the requesting scientist.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren